Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell Lymphoma

NCT00004197 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT00004197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell Lymphoma
Lead sponsor
University of Nebraska
Phase
Phase 2
Overall status
Completed
Start date
June 25, 1999
Completion date
November 20, 2003
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma